360 Stem Cell & Regenerative Medicine Newsletter- September 22, 2015

 weSRCH's Best of the Internet Award
  22nd-Sep-2015
 319

Share: FacebookTwitterLinkedInGoogle

360 Stem Cell & Regenerative Medicine Newsletter - Sept 22, 2015

Featured Video from WSCS14 San Antonio: WSCS14 RegMed Solutions for Orthopedic Injuries and Extremity Regeneration

This week’s video is a very well received session from the World Stem Cell Summit archives. The 60-minute panel was part of the 2014 Regenerative Services “Here and Now” track. The presenters are William L. Murphy, PhD (University of Wisconsin), Chris Rathbone, PhD (U.S. Army Institute of Surgical Research) and Dmitry Tuder, MD (San Antonio Military Medical Center).

World Stem Cell Summit

The Independent (UK): IVF Embryos to be Genetically Manipulated as Scientists Investigate Repeated Miscarriages
“The genetic manipulation of human IVF embryos is set to start in Britain for the first time following a license application by scientists who want to understand why some women suffer repeated miscarriages. If the research license is granted by the UK Government’s fertility watchdog it will be only the second known occasion in the world where the chromosomes of human embryos have been genetically manipulated using a revolutionary gene-editing technique called Crispr/Cas9.”
Editor’s note: This is not without controversy.

Till & McCulloch meetings

Important Breakthrough from Diabetes Research Institute (DRI): First Patient In BioHub Trial No Longer Requires Insulin Therapy
“The Diabetes Research Institute (DRI), a Center of Excellence at the University of Miami Miller School of Medicine, announced that the first patient transplanted in its clinical trial has been free from insulin injections in record time following the implantation of islet cells within a biological scaffold. The patient, Wendy Peacock, 43, from San Antonio, TX, underwent the minimally invasive procedure on August 18, 2015, and is now producing her own insulin naturally for the first time since being diagnosed with type 1 diabetes at age 17. In this pilot study, DRI researchers are testing a new transplant technique for insulin-producing cells, building upon decades of progress in clinical islet transplantation. The trial is an important first step toward the development of the DRI BioHub, a bioengineered mini-organ that mimics the native pancreas to restore natural insulin production in people with type 1 diabetes.”

UPDATE: FIRST PROVISIONAL AGENDA POSTED FOR WORLD STEM CELL SUMMIT & REGMED CAPITAL CONFERENCE, ATLANTA, DEC. 10-12


Click here to view first posted agenda
See first 140 confirmed speakers here.

Only 4 weeks left for “early- bird” discounts- REGISTER TODAY

New confirmed speakers:

David G. Lott, MD
Laryngeal Surgery / Otolaryngology-Head & Neck Surgery
Mayo Clinic
Rochester, MD

Doris A. Taylor, Ph.D., FAHA, FACC
Director, Regenerative Medicine Research
Texas Heart Institute at St. Luke's Episcopal Hospital
Texas Medical Center
Houston, TX

John E. Wagner, MD
Director, Blood and Marrow Transplantation, Department of Pediatrics
Professor, Department of Pediatrics
Scientific Director, Stem Cell Institute
Co-Director, Center for Translational MedicineUniversity of Minnesota Minneapolis, MN

The Daily Star via BBC Online: Lab-grown Kidneys Work in Animals
“Scientists say they are a step closer to growing fully functioning replacement kidneys, after promising results in animals. When transplanted into pigs and rats, the kidneys worked, passing urine just like natural ones. Getting the urine out has been a problem for earlier prototypes, causing them to balloon under the pressure. The Japanese team got round this by growing extra plumbing for the kidney to stop the backlog.”

Biobridge Global

The Sydney Morning Herald: Mesoblast Stem Cell Therapy Approved by Japanese Health Watchdog
“Mesoblast has won full regulatory approval for its first stem cell therapy from the Japanese health regulator, paving the way for the biotechnology company to receive royalties to fund expensive clinical trials. The Japanese Ministry of Health, Labour, and Welfare gave Mesoblast's partner JCR Pharmaceuticals full approval for TEMCELL, which is used to treat graft versus host disease. The disease is a common complication of bone marrow transplants often required by cancer patients. “

Life Interrupted

World Scientific's Latest Book Authored by Stem Cell Advocate Don Reed to be Launched on Stem Cell Awareness Day
“World Scientific's latest book, Stem Cell Battles: Proposition 71 and Beyond How Ordinary People Can Fight Back against the Crushing Burden of Chronic Disease -- with a posthumous Foreword by Christopher Reeve, authored by Fremont author Don C. Reed combines easy-to-understand science, in-the-trenches political warfare, and inspirational stories that capture the struggles that led to Proposition 71,”
360 Editor’s note: One person CAN make a difference. Author Don Reed is the “grandfather” of stem cell advocates- present from the very beginning of the movement. Dedicated to advancing research on spinal cord injury, he lobbied successfully for California’s Roman Reed Act- that funded millions over the years for valuable research. As an early proponent for stem cell research, Don was a valued leader of the original grassroots group, the Stem Cell Action Network (SCAN) and is considered California’s most dedicated champion for Prop 71 and CIRM. Don never gives up. Any success that I have had as an advocate would not have occurred without the early encouragement and support provided to me by my friend Don Reed.

The San Diego Union-Tribune: An Ambitious Proposal Marches On- Stem Cell Treatment for Parkinson's Looks for Funding from CIRM
Journalist Bradley Fikes has written an interesting article focused on the efforts of Parkinson’s grassroots organizations in California seeking funding from the Stem Cell Agency for dollars to fund translation. With the advent of “CIRM 2.0”, the Agency has accelerated the process for approvals and funding.

Icems

Eureka Alert: NYSCF and Q-State Biosciences Collaborate to Create Patient-specific Stem Bells from Blood
“The New York Stem Cell Foundation (NYSCF) and Q-State Biosciences (Q-State) are partnering in a joint research collaboration to advance patient care for nervous system disorders through precision medicine. Through this collaboration, both organizations will further advance their respective technologies, while exploring how their proprietary research platforms might provide synergies in the process of developing novel therapeutics and companion diagnostics.”

HealthCanal: Case Western and Harvard Researchers Pursue Ideal Ingredients for Cartilage Recipe
“A 5-year, $2 million grant from the National Institutes of Health will allow researchers at Case Western Reserve University and Harvard University to build a microfactory that churns out a formula to produce joint cartilage. The team expects to test and analyze more than 3,000 combinations of factors that may influence cell development, including different types and amounts of biochemicals, extracellular matrix properties, compressive stresses and more. They hope to begin testing conditions identified from these studies in animal models by the end of the grant term.”

wiley

Case Western’s Arnold Caplan Receives Lifetime Achievement Award
“Arnold I. Caplan, PhD, professor of Biology and director of the Skeletal Research Center at Case Western Reserve University, received the MSC Lifetime Achievement Award last month at the National Center for Regenerative Medicine’s Mesenchymal Stem Cell conference.”
360 editor’s note: Arnie Caplan is often referred to as the “father” of MSC’s. His path-finding studies have been the springboard to multiple clinical trials and potential treatments. Arnie is a true mentor. Seek him out at the upcoming World Stem Cell Summit in December.

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute




Stem Cells and the Transformative Power of Hope-a TEDx talk by Bernard Siegel, Editor of 360 Newsletter

About GPI

The nonprofit Genetics Policy Institute (GPI) seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn


Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) Announce Merger Plan

Domain: Medical
Category: Biology

Recent Newsletters

Linley Newsletter: August 8, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #664 August 8, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry E

08 August, 2019

Linley Newsletter: August 1, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #663 August 1, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry E

01 August, 2019

Linley Newsletter: July 25, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #662 July 25, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry

25 July, 2019